Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $60.47 Consensus PT from Analysts

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has earned an average recommendation of “Moderate Buy” from the eighteen research firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, fourteen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $60.4706.

RARE has been the subject of several recent research reports. The Goldman Sachs Group cut shares of Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating and decreased their price target for the company from $61.00 to $25.00 in a research report on Tuesday, March 24th. Robert W. Baird decreased their price objective on shares of Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating for the company in a research report on Tuesday, December 30th. JPMorgan Chase & Co. decreased their price objective on shares of Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an “overweight” rating for the company in a research report on Thursday, March 12th. Truist Financial upgraded shares of Ultragenyx Pharmaceutical to a “strong-buy” rating in a research report on Wednesday, March 25th. Finally, Wells Fargo & Company decreased their price objective on shares of Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating for the company in a research report on Tuesday, December 30th.

Insider Activity at Ultragenyx Pharmaceutical

In other news, EVP Eric Crombez sold 7,029 shares of the stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $22.80, for a total transaction of $160,261.20. Following the completion of the sale, the executive vice president directly owned 76,301 shares in the company, valued at $1,739,662.80. This represents a 8.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Howard Horn sold 4,683 shares of the stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $20.97, for a total transaction of $98,202.51. Following the transaction, the chief financial officer directly owned 80,351 shares in the company, valued at approximately $1,684,960.47. This represents a 5.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 109,556 shares of company stock valued at $2,490,138 over the last 90 days. 5.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Several hedge funds and other institutional investors have recently bought and sold shares of RARE. Assetmark Inc. increased its stake in Ultragenyx Pharmaceutical by 1,706.7% in the third quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 1,024 shares in the last quarter. Huntington National Bank lifted its stake in shares of Ultragenyx Pharmaceutical by 56.2% in the third quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 393 shares in the last quarter. Danske Bank A S bought a new position in shares of Ultragenyx Pharmaceutical in the third quarter valued at $39,000. Smartleaf Asset Management LLC lifted its stake in shares of Ultragenyx Pharmaceutical by 205.4% in the third quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 1,169 shares in the last quarter. Finally, Covestor Ltd lifted its stake in shares of Ultragenyx Pharmaceutical by 26.0% in the third quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock valued at $54,000 after buying an additional 369 shares in the last quarter. 97.67% of the stock is owned by institutional investors.

Ultragenyx Pharmaceutical Stock Performance

Shares of NASDAQ RARE opened at $22.87 on Friday. Ultragenyx Pharmaceutical has a 52-week low of $18.29 and a 52-week high of $42.37. The firm has a 50 day moving average price of $22.17 and a two-hundred day moving average price of $27.70. The stock has a market cap of $2.25 billion, a P/E ratio of -3.92 and a beta of 0.25.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. The business had revenue of $207.28 million during the quarter, compared to analyst estimates of $199.60 million. During the same quarter last year, the company posted ($1.39) earnings per share. The company’s revenue was up 25.5% compared to the same quarter last year. Analysts predict that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current fiscal year.

Trending Headlines about Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: FDA accepted Ultragenyx’s resubmitted BLA for UX111, triggering a September 2026 decision date and prompting analyst coverage noting share gains. RARE Rises as FDA Accepts Resubmitted BLA for Sanfilippo Syndrome
• Negative Sentiment: Multiple law firms (Rosen, Faruqi & Faruqi, Schall, DJS, Bronstein Gewirtz & Grossman and others) issued class‑action reminders and urged investors to contact counsel ahead of an April 6, 2026 lead‑plaintiff deadline — highlighting an existing securities suit covering Aug. 3, 2023–Dec. 26, 2025. The flurry of notices can amplify downside risk and headline-driven volatility. RARE DEADLINE TODAY: ROSEN… RARE FINAL DEADLINE ALERT: Faruqi & Faruqi RARE Investors Have Opportunity to Lead…

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.